HALIFAX, July 3 /CNW/ - Origin BioMed Inc., a manufacturer of
over-the-counter topical drug products, announced today it has secured
$3.8 million in funding, led by Calgary-based Avrio Ventures, along with
co-investors Nova Scotia Business Inc. (NSBI) Venture Capital and several
private individuals. This new investment will help drive the company's North
American market expansion, placing Origin's leading diabetic neuropathy
products - including Neuragen(R), a topical oil for fast-acting relief of
diabetic foot pain - on American drug store shelves. Origin will also open a
US office as part of this expansion.
